Metformin sensitises osteosarcoma to chemotherapy < em > via < /em > the IGF-1R/miR-610/FEN1 pathway

Metformin can enhance cancer cell chemosensitivity to anticancer drugs. IGF-1R is involved in cancer chemoresistance. The current study aimed to elucidate the role of metformin in osteosarcoma (OS) cell chemosensitivity modulation and identify its underlying mechanism in IGF-1R/miR-610/FEN1 signalling. IGF-1R, miR-610, and FEN1 were aberrantly expressed in OS and participated in apoptosis modulation; this effect was abated by metformin treatment. Luciferase reporter assays confirmed that FEN1 is a direct target of miR-610. Moreover, metformin treatment decreased IGF-1R and FEN1 but elevated miR-610 expression. Metformin sensitised OS cells to cytotoxic agents, while FEN1 overexpression partly compromised metformin ’s sensitising effects. Furthermore, metformin was observed to enhance adriamycin’s effects in a murine xenograft model. Metformin enhanced OS cell sensitivity to cytotoxic agentsvia the IGF-1R/miR-610/FEN1 signalling axis, highlighting its potential as an adjuvant during chemotherapy.
Source: European Journal of Histochemistry - Category: Biomedical Science Authors: Source Type: research